Cabergoline Overview, Dosing & Safety | Peptide Database

Cabergoline (Dostinex)

Dopamine Agonist | Prolactin Management

Community Research

Join others researching Cabergoline — share findings, ask questions, and learn from real experiences

Cabergoline is a potent, long-acting dopamine D2 receptor agonist that powerfully suppresses prolactin secretion from the anterior pituitary. It is FDA-approved under the brand name Dostinex for the treatment of hyperprolactinemic disorders, including prolactin-secreting pituitary adenomas (prolactinomas). In the bodybuilding and performance enhancement community, cabergoline is considered an essential ancillary compound when running 19-nor anabolic steroids such as nandrolone (Deca-Durabolin, NPP) and trenbolone, both of which can elevate prolactin levels through progestogenic activity. Elevated prolactin causes a range of undesirable effects including gynecomastia (particularly the progesterone-mediated variant), sexual dysfunction (erectile dysfunction, decreased libido, anorgasmia), mood disturbances, and lactation. Cabergoline's exceptionally long half-life of 63-69 hours allows for convenient twice-weekly dosing, and its high affinity for D2 receptors makes it significantly more potent and better tolerated than the older dopamine agonist bromocriptine.

Cabergoline exerts its effects by acting as a potent agonist at dopamine D2 receptors on lactotroph cells in the anterior pituitary gland. Prolactin secretion is tonically inhibited by hypothalamic dopamine acting on these D2 receptors, and cabergoline mimics this inhibitory signal with high affinity and prolonged duration. By activating D2 receptors, cabergoline suppresses prolactin gene transcription, reduces prolactin synthesis, and inhibits prolactin release into the bloodstream. In patients with prolactinomas, cabergoline also induces tumor shrinkage by inhibiting lactotroph cell proliferation and promoting apoptosis. The drug's selectivity for D2 receptors over D1 receptors contributes to its favorable side effect profile compared to less selective dopamine agonists. In the context of 19-nor steroid use, nandrolone and trenbolone stimulate prolactin release through their progestogenic activity, and cabergoline directly counteracts this elevation by restoring dopaminergic inhibition at the pituitary level.

Molecular Data

Research Indications

Nandrolone (Deca-Durabolin and NPP) elevates prolactin through progestogenic activity. Cabergoline is considered the gold standard for preventing and treating prolactin-related side effects during nandrolone cycles, including sexual dysfunction and progesterone-mediated gynecomastia.

Trenbolone is a potent progestin that can significantly elevate prolactin in some users. Cabergoline controls prolactin-driven side effects such as lactation, nipple sensitivity, erectile dysfunction, and anorgasmia that may occur during trenbolone cycles.

Elevated prolactin from 19-nor compounds commonly causes decreased libido, erectile dysfunction, and difficulty reaching orgasm (often called 'deca dick'). Cabergoline restores normal sexual function by normalizing prolactin levels.

FDA-approved for the treatment of hyperprolactinemic disorders of various etiologies, including idiopathic hyperprolactinemia and prolactin-secreting pituitary adenomas (micro- and macroadenomas). Normalizes prolactin in over 85% of patients.

First-line medical therapy for prolactin-secreting pituitary tumors. Cabergoline achieves significant tumor size reduction in the majority of patients, often avoiding the need for surgical intervention.

Dosing Protocols

Cabergoline is administered orally as a tablet, typically 0.5mg per tablet. It has good oral bioavailability and its absorption is not significantly affected by food, though taking it with food can reduce gastrointestinal side effects. The exceptionally long half-life of 63-69 hours allows for twice-weekly dosing in both medical and bodybuilding contexts, making it one of the most convenient prolactin management options available.

Prolactin management during 19-nor cycle (preventive)

0.25mg

Twice weekly

Oral

Prolactin management during 19-nor cycle (active symptoms)

0.5mg

Hyperprolactinemia treatment (medical, initial)

Once weekly (may split into two 0.25mg doses)

Hyperprolactinemia treatment (medical, maintenance)

0.5-1mg

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Nausea (especially during initial doses; mitigated by taking with food)

Dizziness or lightheadedness

Headache

Nasal congestion or stuffiness

Fatigue or drowsiness

Orthostatic hypotension (feeling faint when standing up quickly)

Stop Signs - Discontinue if:

Signs of cardiac valve dysfunction (new onset shortness of breath, chest pain, peripheral edema, exercise intolerance)

Severe or persistent dizziness or fainting episodes

Emergence of compulsive or impulsive behaviors (gambling, spending, hypersexuality)

Persistent psychiatric symptoms (hallucinations, paranoia, severe mood changes)

Signs of fibrotic complications (unexplained back pain, leg swelling, breathing difficulty)

Contraindications

Known hypersensitivity to cabergoline or any ergot alkaloid

History of cardiac valvular disease or clinically significant valvular regurgitation

History of pulmonary, pericardial, or retroperitoneal fibrotic disorders

Uncontrolled hypertension

Concurrent use of dopamine antagonists (antipsychotics, antiemetics acting on D2 receptors)

Severe hepatic impairment (cabergoline is extensively metabolized by the liver)

Quality Checklist

Good Signs

White to off-white crystalline powder or uniform tablets

Third-party certificate of analysis (COA) confirming identity and purity (>98%)

HPLC or mass spectrometry testing verifying cabergoline content and absence of contaminants

Professional packaging with batch number, expiration date, and proper labeling

Sourced from a licensed pharmacy, compounding pharmacy, or reputable research supplier

Standard 0.5mg tablet dosing for easy protocol adherence

Warning Signs

No COA or third-party testing available

Tablets are inconsistent in size, color, or hardness

Product labeled generically without specific compound identification

Packaging lacks batch number or expiration date

Bad Signs

Discolored, crumbling, or visibly degraded tablets

Unusual chemical odor or taste

No labeling, batch information, or expiration date

COA shows significant impurities or incorrect compound identity

Sourced from unverified vendors with no quality documentation

Frequently Asked Questions

Is cabergoline necessary on a testosterone-only cycle?

No. Testosterone itself does not significantly elevate prolactin. Cabergoline is primarily needed when running 19-nor anabolic steroids like nandrolone (Deca-Durabolin, NPP) or trenbolone, which have progestogenic activity that drives prolactin elevation. On testosterone-only cycles, cabergoline is unnecessary unless prolactin is elevated from another source.

Why is cabergoline preferred over bromocriptine?

Cabergoline is significantly more potent and better tolerated than bromocriptine. It requires only twice-weekly dosing (vs daily for bromocriptine), normalizes prolactin in ~83% of patients versus 59% for bromocriptine, and causes fewer gastrointestinal side effects. The 63-69 hour half-life allows convenient dosing schedules.

Can cabergoline cause side effects if prolactin is too low?

Yes. At high doses or if dopaminergic stimulation is excessive, cabergoline can lower prolactin below optimal levels, potentially causing emotional blunting, anhedonia, or compulsive behaviors. On typical 0.25-0.5 mg twice-weekly bodybuilding doses, this is uncommon, but monitoring mood is important.

What dose of cabergoline do I need for a 19-nor cycle?

Preventive dosing is typically 0.25 mg twice weekly during nandrolone or trenbolone cycles. If prolactin-related symptoms develop (sexual dysfunction, lactation), increase to 0.5 mg twice weekly. Baseline prolactin testing before the cycle helps guide dosing and confirm the compound is working effectively.

References

Landmark randomized trial comparing cabergoline with bromocriptine in 459 hyperprolactinemic women. Cabergoline normalized prolactin in 83% of patients versus 59% for bromocriptine, with significantly fewer side effects including less nausea, vomiting, and dizziness. Established cabergoline as the preferred dopamine agonist for hyperprolactinemia.

Large multicenter study of 455 patients treated with cabergoline for hyperprolactinemia. Normalization of prolactin was achieved in 86% of patients with idiopathic hyperprolactinemia and 89% of patients with microprolactinomas. Tumor shrinkage of greater than 50% was observed in the majority of macroprolactinoma patients. Confirmed excellent long-term tolerability.

Prospective study evaluating cardiac valve status in prolactinoma patients on long-term cabergoline therapy at standard doses. Found no significant increase in clinically relevant valvular heart disease compared to controls at the doses used for hyperprolactinemia (typically 0.5-2mg/week), in contrast to the high doses used in Parkinson's disease (3-7mg/day). Provided reassurance for standard-dose, long-term use.

Comprehensive review of cabergoline pharmacology and clinical efficacy. Detailed the drug's pharmacokinetic profile including its 63-69 hour half-life, high D2 receptor affinity, and oral bioavailability. Demonstrated superior efficacy and tolerability compared to bromocriptine across multiple clinical endpoints.

Official Endocrine Society guideline recommending cabergoline as the first-line pharmacological treatment for hyperprolactinemia due to its superior efficacy, tolerability, and convenient dosing schedule. Recommended echocardiographic monitoring for patients on long-term therapy, particularly at higher doses, though noted that cardiac risk at standard hyperprolactinemia doses appears low.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.